Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma.

BMC Cancer · 2024 · PMC11386351 · PMID 39251979

Europe PMC DOI

hedged sentence

0.0850

closest p · 1.7× alpha

0.0850

boldest claim

The sentences

showed a trendp = 0.085so close (0.05 < p ≤ 0.1)

In non-transplanted patients, VRD showed a trend towards improved five-year OS ( p = 0.085) and PFS ( p = 0.073) compared to the PAD group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.